I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

The extracellular vesicles (EVs) are secreted by cells and recycled in body fluids, which are collective term covering the name of exosomes, microvesicles (MVs), microparticles, ectosomes, oncosomes, and apoptotic bodies. The difference of the above terms depends on the size. The oncosomes, ability to transfer oncogenic material, exhibit their atypical large size (1--10 μm). MVs are ranged in size from 50 to 1000 nm in diameter. The exosomes are ranged from 60 to 200 nm \[[@ref1]\]. The isolations of apoptotic bodies or ectosomes are obtained by the procedures of \~300--500 ×g (removing cells), followed by force at \~1000 ×g to remove cellular debris, and finally followed by a longer centrifugation at higher g forces (\~10,000\< × \< \~16,000 ×g). The most commonly used method for isolating exosomes is ultracentrifugation (UC) at 100,000--120,000 ×g \[[@ref2]\]. The components of EVs include lipids and proteins in addition to nucleic acids. Moreover, EVs feature the property of the cell sources. The minimal information for studies of EVs 2018 (MISEV2018) has claimed some criteria for EVs. The general characterization of EVs according to MISEV2018 would contain at least three positive protein markers of EVs, including at least one transmembrane/lipid-bound protein and cytosolic protein, and at least one negative protein marker. The importance of the ratio of proteins to particles has been mentioned in the MISEV2018. Apart from the definition from MISEV2018, the other term might be more appropriate as an extracellular particle \[[@ref3]\]. Exosomes have been used as pathological markers \[[@ref4]\], gene carrier, and drug carrier \[[@ref5]\]. The size of exosomes is 60-200 nm and owing to its biocompatibility, exosomes have great potential for use as anti-cancer drug vehicles. In order to ensure the biological activity of exosomes, a standardized manufacturing process, such as a process in compliance with good manufacturing practice (GMP), of exosomes is vital.

Because exosomes are secreted by cells, a production system could be established using a large-scale cell cultivation system. The downstream purification system should preferably conform to the procedures of vaccine production because of the similarity in particle size and features of secretory vesicles of the host cells. The challenge in GMP of exosomes is quality control. Although markers of exosomes have been defined by previous studies, the type of cells producing exosomes is diverse \[[@ref6][@ref7]\]. Most reviews have focused on the generation and application of exosomes in preclinical or clinical trials \[[@ref5][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17]\]. Therefore, this article concisely reviews exosomes in clinical trials and their production in compliance with GMP. Three main criteria, including upstream of cell cultivation system, downstream of the purification system, and quality control of exosomes, are discussed for GMP. Exosomes from human and plant sources involved in clinical trials are mentioned in the article \[[Figure 1](#F1){ref-type="fig"}\].

![Summary of exosomes in clinical trials and flow chart for exosome production in compliance with good manufacturing practice. DC: Dendritic cells, MSC: Mesenchymal stem cell, LC-MS: Liquid chromatography--mass spectrometry](TCMJ-32-113-g001){#F1}

E[XOSOME PRODUCTION FOLLOWING GOOD MANUFACTURING PRACTICE]{.smallcaps} {#sec1-2}
======================================================================

An exosome is a monolayer of small vesicles with a diameter of 60-200 nm formed by cytoplasmic membrane invagination. Exosomes are widely distributed in all tissues, intercellular spaces, and body fluids. Almost all cells secrete exosomes. Exosomes, similar to a postman, can be accurately transmitted to specific organ cells through cell surface receptors for cell--cell transmission \[[@ref7]\].

The methods for the production of GMP-grade exosomes in recent years are shown in [Table 1](#T1){ref-type="table"}. A GMP-grade exosome production method includes the type of cells, culture environment, cultivation system, dissociation enzyme, and culture medium. Further purification is required after production, generally divided into three-step process. The third issue in GMP of exosomes is the establishment of identification method, including physical structure and bioactivity function characteristics.

###### 

Summary of the methods for exosome production in compliance with good manufacturing practice

  Cell expansion   Exosome isolation                               Exosome validation   Results                                           Reference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  ---------------- ----------------------------------------------- -------------------- ------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------- --------------------------------------------------- ----------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  MDDCs            T-175 flasks                                    Not reported         Serum-free                                        3/0.8 μm filter                                        500-kDa MWCO hollow fiber membrane                       Sucrose/deuterium UC at 100,000 ×g                  ELISA                         Tetraspanin proteins, such as CD81, CD63, CD9, and CD82; costimulatory molecule CD86; adhesion proteins, such as CD11b, CD11c, CD58, and CD54   Not reported                              Increased quantity (concentration of MHC class II) and protein characterization (using FACS) to standardize exosome vaccine   Journal of immunological methods 2002, 270 (2), 211-26 \[[@ref18]\]
  BM-MSCs          T225 flask                                      Not reported         HPL/FBS                                           0.22 μm filter                                         UC at 30,000 × g for 20min                               UC at 120,000 ×g for 3h                             Not reported                  CD90, CD14, CD34, CD45, CD73; HLA-II (DR); total RNA; miRNA                                                                                     NTA                                       10% HPL-based EV-depleted medium is appropriate for the purification of exclusively human MSC-derived EVs                     Cytotherapy, 2017; 19: 458-472 \[[@ref19]\]
  hCPCs            CellBIND®                                       TrypLETM Select      Free of nonhuman animal-derived components        Centrifugation (3000 × g) and filtration (0.22 μm)     Amicon Ultra-15 (100 kDa cut-off) or Centricon Plus-70   TFF with a 300-kDa cut-off hollow fiber cartridge   QuantiProTM BCA assay kit     GATA4, TBX5, TBX18, MESP1, TSG101, GRP94, and GAPDH                                                                                             TEM                                       High exosome yield, and consistent removal of contaminating proteins (97%)                                                    Front Physiol. 2018; 9: 1169 \[[@ref20]\]
  HEK293 cell      Hollow-fiber bioreactors (fibercell systems)    Not reported         EV-depleted cell culture medium                   Differential centrifugation and filtration (0.22 μm)   TFF device (0.05 μm pore size)                           UC at 110,000 ×g for 3 h SEC                        Bradford assay                CD63 and calnexin                                                                                                                               NTA; immune-TEM; LC-MS                    Combination TFF and SEC for large staring volumes                                                                             J Extracell Vesicles 2018, 7 (1), 1442088 \[[@ref22]\]
  BM-MSCs          Hollow-fiber bioreactors (quantum bioreactor)   \-                   HPL for confluence then HPL-free for collection   Centrifugation (1000 × g) and 0.2-μm filters           Not applied                                              UC at 110,000 ×g for 3 h                            MicroBCA assay                Exosome markers (CD9, CD63, CD81, and CD47); mesenchymal markers (CD29 and CD90); siRNA sequence                                                NanoSight; TEM                            Shelf life, biodistribution, toxicology profile, and efficacy                                                                 JCI Insight. 2018 Apr 19; 3 (8) \[[@ref21]\]
  ADSC; BM-MSCs    Flasks                                          Trypsin-EDTA         PL                                                Centrifugation at 3000 × g for 20 min                  Not applied                                              UC: 100,000 ×g for 1 h at 4°C UF: Purified by TFF   Micro BCA-protein assay kit   Cytokine quantification by; Immunogenicity and immunomodulatory properties; Secretome versus. MSC immunomodulatory properties                   NTA; phospholipid quantification; FT-IR   UF lead to higher protein, lipid, cytokine, and exosome yield compared with that with UC                                      Nanomedicine 2019, 14 (6), 753-765 \[[@ref23]\]

MDDCs: Monocyte-derived dendritic cells, BM-MSCs: Bone marrow-mesenchymal stem cells, hCPCs: Human cardiac progenitor cells, ADSC: Adipose-Derived Stem Cell, PL: Platelet lysate, HPL: Human platelet lysate, FBS: Foetal bovine serum, EV: *Extracellular vesicles*, EDTA: Ethylenediaminetetraacetic acid, UC: Ultracentrifugation, TFF: Tangential flow filtration, SWC: Size-exclusion chromatography, UF: Ultrafiltration, NTA: Nanoparticle tracking analyzer, TEM: Transmission electron microscopy, LC-MS: Liquid chromatography-mass spectrometry, SEC: Size-exclusion chromatography, MWCO: Molecular weight cut-off, BCA: Bicinchoninic acid, FACS: Fluorescence-activated cell sorting, MHC: Major histocompatibility complex, HLA-II (DR): Human Leukocyte Antigen II -- DR isotype, FT-IR: Fourier-transform infrared spectroscopy

Upstream of cell culturing system for setting an exosome-secreting environment {#sec2-1}
------------------------------------------------------------------------------

Five types of cells, including human cardiac progenitor cells, bone marrow mesenchymal stem cells (MSCs), adipose tissue-derived stem cells, monocyte-derived dendritic cells (DCs), and HEK293 cells, have been applied in GMP for exosome production. Cell cultivation employs static systems, such as a flask, as well as dynamic systems, such as a bioreactor. Two types of static flask system used include stand tissue culture flask \[[@ref18][@ref19]\] and CellBIND^®^ surface. The CellBIND^®^ surface is pretreated with oxygen-containing functional group and has a net negative surface charge \[[@ref20]\]. Bioreactors are also used for large-scale production because of the dynamic monitoring system, which is beneficial for the GMP process \[[@ref21][@ref22]\]. Because the size of exosomes is around 60-200 nm, the hollow fiber bioreactor system with molecular weight cutoff membrane is employed for condition medium (CM) harvest. The hollow fiber bioreactor system provides a dynamic environment for cell cultivation and a continuous medium collection system. The collection system provides the reduced volume of harvested CM that benefits for downstream purification. Both animal-free \[[@ref20]\] and animal-derived \[[@ref23]\] dissociation enzymes are utilized in the process. The cultivation medium differs based on the source of the cells, but it can be classified into animal-free \[[@ref18][@ref20]\] or animal-derived \[[@ref21]\] components. The process of GMP for exosome can be improved in many aspects to obtain more and purer exosomes. For examples, using xeno-free conditions to culture cells can reduce the doubling time and lead to high exosome yield and consistent removal of contaminating proteins up to 97% \[[@ref20]\]. Furthermore, the 10% pooled human platelet lysate (HPL)-based EV-depleted medium, which is suitable for the production of human MSC-derived exosomes as it retains the characteristic surface marker expression, cell morphology, viability, and *in vitro* differentiation potential, can be used \[[@ref19]\].

The advantage of static flask system is less skilled labor comparing to that of bioreactor. If the cultivation system requires specific parameters such as CO~2~, O~2~, pH to manipulate, the bioreactor would be an attractive method. The most common cultivation reagent of dissociation enzymes or medium should be animal free for avoiding the pathogenic source or ethical issue. In some studies have mentioned that the HPL showed the greater bioactivity than traditional medium. Therefore, the reagent choose would be considered in the further clinical application.

Downstream of purification system for exosomes {#sec2-2}
----------------------------------------------

In general, there are three steps of purification, including filtration for removing the cell debris, concentrating the CM, and exosome isolation from the concentrated CM. The differential centrifugation is the common strategy for the concentration of CM and exosome isolation from the concentrated CM. Although a less additive reagent is added during differential centrifugation comparing to that of sucrose gradient method, workforce, and labor are the disadvantages of the differential centrifugation purification \[[@ref24]\].

Tangential flow filtration (TFF) is an alternative method for the concentration of CM and purification of exosomes in recent years owing to the advantages of less time and workforce for large-scale purification. In addition, the performance of TFF and UC has been compared. Exosomes obtained from TFF exhibit higher immunomodulatory potency than those from UC. Moreover, the immunomodulatory potency of exosomes from TFF is similar to that of the parental cells, confirming the rationality of replacing cells with their secreted exosome. The reports showed that more soluble factors, such as cytokines, DNA, RNA, proteins, or lipids, are contained in the exosomes obtained from TFF than in those from UC. EV aggregation or destruction is observed after harvesting exosomes by UC because elevated shear forces in UC may break down the exosomes and thus, the proteins released from exosomes \[[@ref23]\]. In addition, size-exclusion chromatography (SEC) is a method developed based on the size exclusion theory for exosome purification. Compared to exosomes from UC, a 100-fold reduction in ferritin, a major protein complex contaminant, concentration is observed in SEC-purified exosomes \[[@ref22]\].

We specifically explored whether to use commercially available ExoQuick™ as a purification process, but none of the other GMP production processes discussed in this article were verified. According to our unpublished research results, the purification method using ExoQuick™ is fast and convenient, but the purified sample still contains the contaminate proteins from culturing medium; therefore, it is only suitable for exosome preparation in the research stage.

The purification of exosomes involved the criteria of recovery rate and specificity. In general, to achieve a higher recovery would decrease the specificity and vice versa. This is because higher specificity achievement should follow step-by-step purification procedure to remove un-purity matters. The advantages of differential centrifugation are to obtain a high purity of exosomes; however, the recovery rate would be lost in each step of differential centrifugation and time-consuming of differential centrifugation is one of the disadvantages. Therefore, sucrose gradient centrifugation overcomes the time consuming and maintenance of purity of exosomes. The one disadvantage of sucrose gradient centrifugation is the residues of sucrose reagent. The system of ultrafiltration brings more attractive features in overcoming of time-consuming, increased specificity, and recovery rate. However, the protein may suffer in-stable in the ultrafiltration system because the CM is concentrated in the purification process and thus may cause a raised osmotic pressure.

Exosome characterization -- Physicochemical and biological properties {#sec2-3}
---------------------------------------------------------------------

The adsorption of protein and protein content in exosomes is determined by ELISA and sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) \[[@ref18]\]. Another alternative method using a BCA-protein assay kit has been developed for protein quantification \[[@ref20][@ref21][@ref23]\]. With the progress in technology, a microfluidic electrophoresis analyzer \[[@ref19]\] and liquid chromatography--mass spectrometry \[[@ref22]\] have been established for the analysis of exosome components. To quantify the cytosolic proteins from parent cells and exosome markers, such as CD9, CD63, and CD81, flow cytometry is used.

Recent literature has indicated that physicochemical properties of exosomes, such as particle size and concentration, can be determined using NanoSight instruments and transmission electron microscopy (TEM) to observe the structure and size of exosomes. In addition, studies have described methods such as phospholipid quantification, cytokine quantification, and immunomodulatory properties for identifying exosomes \[[@ref23]\].

E[XOSOMES IN CLINICAL TRIALS]{.smallcaps} {#sec1-3}
=========================================

Two categories of exosomes are applied in clinical trial, namely, exosomes derived from plants and human specimen \[[Figure 1](#F1){ref-type="fig"}\]. Until now, completed results of clinical trials using exosomes from human specimens have been reported; by contrast, plant derived exosomes are in the beginning stage, patients were not yet recruited in clinical trials. Due to the vesicle structure of exosomes, using exosomes as a drug carrier has also been performed in clinical trials. [Table 2](#T2){ref-type="table"} describes the exosome applied in clinical trials having complete clinical reports, and [Table 3](#T3){ref-type="table"} summaries the development of exosomes in clinical trials in the recruiting-status or not-recruiting status.

###### 

Summary of the exosome used in clinical trials with the complete reported results

  Indication                                                Year, phase, patients             Source                                                     Dose                                              Administration                                                      Purification                                                      Characterization                                                                                Bioactivity                                                                                 Exosome manipulation                                                                  Results
  --------------------------------------------------------- --------------------------------- ---------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  Melanoma \[[@ref35]\]                                     2000, Phase 1, (*n*=15)           imDC, autologous                                           4×10^13^ or 1.3 × 10^13^ MHC Class II molecules   SC (90% of the volume) and ID (10%) injections weekly for 4 weeks   500-kDa concentration and UC with D~2~O/sucrose cushion           CD81 tetraspanin                                                                                SEE test of potency                                                                         Pulsed with MAGE 3 tumor peptides                                                     No Grade II toxicity; No detected MAGE3-specific CD4+ and CD8+ T cells
  Non-small cell lung cancer \[[@ref25]\]                   Not reported. Phase 1, (*n*=4)    imDCs, autologous                                          1.3×10^13^ MHC Class II molecules                 SC (90% of the volume) and ID (10%) injections weekly for 4 weeks   500-kDa concentration and UC with D~2~O/sucrose cushion           Not reported                                                                                    MHC Class II molecules; ELISPOT for peptide-specific immune response                        Pulsed with MAGE-A3, -A4, -A10, and MAGE-3DPO4 tumor peptide                          Well-tolerated and only Grade 1-2 adverse events; MAGE-specific T-cell responses in 1/3 patients; increased NK lytic activity in 2/4 patients
  Non-small cell lung cancer \[[@ref26]\] \[NCT01159288\]   May 2010, Phase 2, (*n*=22)       Mature- dendritic (mDCs), autologous (induced by rIFN-γ)   8.5×10^11^-1.0× 10^13^ MHC Class II molecules     Four ID at 1-week intervals                                         UF; DF and UC through a 1.21g/mL sucrose cushion                  Exosome marker: Tetraspanin                                                                     Activation of LT11 cells Function: MHC class II molecules and CD40, CD86, and ICAM-1/CD54   Pulsed with MAGE-A1, -A3, NY-ESO-1, Melan-A/MART1, MAGE-A3-DP04, EBV tumor peptides   One patient had Grade 3 hepatotoxicity; boosting the NK cell arm of antitumor immunity
  Colon cancer \[[@ref27]\]                                 Not reported, Phase 1, (*n*=40)   Ascites, autologous                                        100-500 μg of protein                             Four SC at weekly intervals                                         Differential centrifugation + sucrose/D~2~O density gradient UC   Exosome marker: HSPs (including HSC70, HSP70, and HSP90), CD80, ICAM-1, CD71), and LAMP-3; EM   Function: Tumor-associated carcinoembryonic antigen, MHC-I, and MHC-II molecules            ±GM-CSF                                                                               Safe, well-tolerated; tumor-specific antitumor CTL response in exosome plus GM-CSF group
  Chronic kidney diseasesc \[[@ref29]\]                     April 2014, Phase 2/3, (*n*=40)   MSCs, allogeneic                                           100 μg/kg/dose                                    Two doses of MSC-EVs, intraarterial and intravenous injections      UC at 100,000 ×g                                                  CD9, CD63; EM                                                                                   CD45, CD73                                                                                  Unmodified                                                                            Safe, well-tolerated; improved kidney function; decreased inflammation

UC: Ultracentrifugation, imDCs: Immature-dendritic cells, SC: Subcutaneous, ID: Intradermal, MSCs: Mesenchymal stem cells, UF: Ultrafiltration, DF: Diafiltration, EM: Electron microscopy, CTL: Cytotoxic T lymphocyte, GM-CSF: Granulocyte-macrophage colony-stimulating factor, NK: Natural killer, MHC: Major histocompatibility complex, ICAM-1: Intercellular adhesion molecule 1, LAMP-3: Lysosomal-associated membrane protein 3, HSP: Heat shock protein, rIFN-γ: Recombinant interferon-γ, EV: *Extracellular vesicles*

###### 

Summary of exosomes used in clinical trials (source: [clinical trials.com](clinicaltrials.com))

  Indication/year                                                                          Year, phase, patients             EV source                            EV dose                                   Administration                                                                  EV manipulation                      Results/status
  ---------------------------------------------------------------------------------------- --------------------------------- ------------------------------------ ----------------------------------------- ------------------------------------------------------------------------------- ------------------------------------ ------------------------
  Malignant ascites and pleural effusion (NCT01854866)                                     May 2013, Phase 2, (*n*=30)       Tumor-derived                        Not reported                              Perfused to the pleural or peritoneal cavity, 4 times/week                      Loaded with chemotherapeutic drugs   Unknown status
  Malignant pleural effusion (NCT02657460)                                                 January 2016, Phase 2, (*n*=90)   Malignant pleural effusion           Not reported                              Not reported                                                                    Loaded with methotrexate             Recruiting
  Metastatic pancreatic cancer (NCT03608631)                                               March 2020, Phase 1, (*n*=28)     MSCs, allogeneic                     Not reported                              IV on days 1, 4, and 10. Treatment repeated every 14 days for up to 3 courses   KrasG12D siRNA (iExosomes)           Not yet recruiting
  Bronchopulmonary dysplasia (NCT03857841)                                                 June 2019, Phase 1, (*n*=18)      MSCs                                 -200 pmol phospholipid/kg                 Intravenous                                                                     Not specified (UNEX-42)              Recruiting
  Type 1 diabetes (NCT02138331)                                                            April 2014, Phase 1, (*n*=20)     MSCs, allogeneic                     (1.22-1.51)×10^6^ cells/kg, Day 0 and 7   Intravenous                                                                     Unmodified                           Unknown
  Macular holes (NCT03437759)                                                              March 2017, Phase 1, (*n*=44)     MSCs, allogeneic                     50 μg or 20 μg                            Dripped into vitreous cavity                                                    Unmodified                           Recruiting
  Acute ischemic stroke (NCT03384433)                                                      April 2019, Phase 1/2, (*n*=5)    MSCs, allogeneic                     200 μg                                    Stereotaxic injection                                                           Enriched by miR-124                  Not yet recruiting
  Colon cancer (NCT01294072)                                                               January 2011, Phase 1, (*n*=35)   Plant-derived                        Not reported                              Tablets taken daily for 7 days                                                  Loaded with curcumin                 Active, not recruiting
  Radiation- and chemotherapy-induced oral mucositis (NCT01668849)                         August 2012, Phase 1, (*n*=60)    Grape derived                        Not reported                              Oral administration daily for 35 days                                           Unmodified                           Active, not recruiting
  Insulin resistance and chronic inflammation in polycystic ovary syndrome (NCT03493984)   May 2018, not applicable          Plant-derived (ginger and/or aloe)   Not reported                              \-                                                                              Unmodified                           Not yet recruiting

IV: Intravenous, EV: Extracellular vesicles, MSCs: Mesenchymal stem cells

Exosomes from human specimen {#sec2-4}
----------------------------

Three major sources, namely DCs, MSCs, and patient-derived tumor cells, of obtaining exosomes, are subjected to clinical trials. Exosomes are purified and processed to concentrated form by UF or differential centrifugation followed by UC with sucrose cushioning. Physical characterization is performed by electron microscopy or by detecting exosome markers, such as CD9, CD81, tetraspanins, heat shock 70 kDa protein 8 (HSC70), heat shock protein (HSP) 70, HSP90, CD80, intercellular adhesion molecule 1, CD71, lysosomal-associated membrane protein 3, CD63, Alix, and tumor susceptibility gene 101 \[[Table 2](#T2){ref-type="table"}\]. Moreover, bioactivity is characterized by the exosome derived source or by methods such as determining the immunogenicity. The application of human-derived exosome is major in cancer indication, and some in inflammatory or chronic disease. The exosomes could contain tumor antigen to induce anti-tumor immunity in a patient or anticancer drug to cause cytotoxicity for the treatment of patients with cancer. Moreover, utilization MSC featuring inflammatory regulation is a strategy to treat inflammatory or chronic disease. The following sections describe the detail information of the application of exosomes.

### Cancer indication {#sec3-1}

Exosomes containing tumor antigen to induce antitumor immunity in a patient

Exosomes from DC could be either from immature or mature DCs activated by cytokines, such as recombinant interferon-γ. The injection dose ranges from 8.5 × 10^11^ to 4.0 × 10^13^ exosomes with MHC class II molecules. To induce the immunity of a patient diagnosed with cancer, the DC-derived exosome harbors tumor peptides to be injected subcutaneously. Trials employing immature DC-derived exosomes have been applied for melanoma and non-small cell lung cancer, for which the results of safety are similar, but in case of non-small cell lung cancer, MAGE-specific T-cell responses have been observed \[[@ref25]\]. To advance T-cell stimulation, the strategy of DC maturation has been designed for patients with nonsmall cell lung cancer. However, one patient had Grade 3 hepatotoxicity, and only 32% of patients experienced stabilization for more than 4 months of progression-free survival, which is less than their primary endpoint of 50% \[[@ref26]\]. Because tumor antigens, such as carcinoembryonic antigen, can be directly derived from a patient with cancer, ascites-derived exosomes from patients were harvested. Safety and well-tolerance in phase I trial have been reported, and a tumor-specific antitumor cytotoxic T lymphocyte response has been observed in the ascites-derived exosomes plus granulocyte-macrophage colony-stimulating factor group \[[@ref27]\].

Exosomes containing anti-cancer drug to cause cytotoxicity for the treatment of patients with cancer

In addition to carrying tumor antigen, exosomes containing chemo drug or siRNA have been used in the treatment of cancer. There are two clinical trials (NCT01854866 and NCT02657460) using chemo drug to treat patients diagnosed with malignant pleural effusion. In the preclinical trial and trial of NCT01854866, they used methotrexate (MTX) and cisplatin as the anticancer drugs, respectively. The survival ratio was higher when MTX was used as the anticancer drug in the preclinical trials \[[@ref28]\]. In the trail of NCT02657460, they used MTX as the encapsulating anticancer drug and cisplatin as the comparator. KrasG12D siRNA has been promoted as another anticancer drug type for the treatment of patients with metastatic pancreas cancer, and the mesenchymal stromal cells-derived exosomes have been proposed in the clinical trial number NCT03608631.

### Other indications {#sec3-2}

There have been few clinical trials that employ DC-derived exosomes after 2013 \[[Table 2](#T2){ref-type="table"}\]. The application of MSC-derived exosomes in clinical trials began in 2014 \[[Table 2](#T2){ref-type="table"}\], and the complete report was available in 2016 \[[@ref29]\]. Most clinical trials using MSC-derived exosomes are applied for chronic diseases, immunity diseases, and acute ischemic stroke. Only one case of a clinical trial using MSC-derived exosomes encapsulating KrasG12D siRNA has been reported. Two clinical trials have reported MSC-derived EVs in treating chronic diseases, namely chronic kidney disease, and bronchopulmonary dysplasia. Due to the less degree of manipulation in exosomes, the characteristics of exosomes can be determined by exosome and MSC markers.

Plant source {#sec2-7}
------------

Three sources of plant namely grape (NCT01668849) and ginger or aloe (NCT03493984), have been registered in clinical trial from the same sponsor, University of Louisville, but the status of clinical trials of plant-derived exosomes is under the not recruiting phase \[[Table 3](#T3){ref-type="table"}\]. The application of grape-derived exosomes is in treating diseases due to radiation- and chemotherapy-induced oral mucositis. In a previous preclinical study, Songwen Ju *et al.* demonstrated that grape-derived exosomes could renew the processes of intestinal tissue and participate in the process of tissue remolding when the tissue suffers from pathological damage \[[@ref30]\]. Another study by Henry Bohler *et al.* used ginger or aloe to produce exosomes for treating patients diagnosed with polycystic ovary syndrome, expecting it to mitigate insulin resistance and chronic inflammation (trial number NCT03493984). Moreover, Donald Miller *et al.* used plant-derived exosomes as a hydrophobic drug delivery carrier to encapsulate curcumin, owing to the hydrophobic character of molecules, for treating intestinal diseases (trial number NCT01294072).

The exosomes from plant feature the advantages of animal-free issue and Chinese herbal medicine theory to support the basic scenario, but the life cycle of the plant too long and less information to provide in the exosome production and characterization. The less doubling time of mammalian cells, around 24--48 h, attractive the development of clinical trials. There is less information on GMP production for plant-derived exosome, but there are some preclinical studies investigated. The majority difference between animal and plant-derived in the production process is the medium harvest. The exosome from the animal-derived is to harvest the medium in the cultivation process. In contrast, the plant-derived exosomes are to extract the apoplastic vesicles, such as leaf, rice shoot, sunflower seed, and root, or the exosome-like vesicles from fruit juices \[[@ref31][@ref32][@ref33]\]. Unfortunately, the characterizations of plant-derived exosome have less information, in particular of specific marker \[[@ref34]\]. However, the most common methods, such as TEM, nanoparticle tracking analysis, and SDS-PAGE, for plant-derived exosome characterizations are similar to that of animal-derived exosome. Therefore, the development of GMP-grade plant-derived exosome, in particular of purification and characterization, may refer to that of animal-derived exosome.

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

Plant- and human tissue-derived exosomes have been registered in clinical trials. Exosomes derived from human tissue are established with more complete reports and data than those of plant-derived exosomes. Most studies describe human tissue-derived exosomes, complying with GMP, to satisfy the application requirements of clinical trials. Exosomes production by cell culture has to be subjected to exosome purification and characterization. A hollow fiber-based bioreactor for cell culture is an attractive strategy for exosome production because of the advantage that decreased volume of CM can be harvest from the filtrated fiber. Moreover, exosomes purified by UF for avoiding bioactive protein release from vesicle of exosomes have higher benefit than those of UC. The determination of biofunctions, such as biomarker of exosomes and properties derived from parental cells, are the two major issues for characterization of exosomes before application in clinical trials. Overall, the development of exosomes may be an alternative candidate for treating diseases of unstratified fields, such as cancer, inflammation diseases, and chronic diseases.
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